In what patient subsets (RA biomarkers, obese, undifferentiated RA, high risk RA, poor responders, etc.) do IL-6 inhibitors appear to be most effective?

Daniel Furst, MD

Professor of Rheumatology
Carl M. Pearson Chair of Rheumatology
Director of Interventional Therapeutics
University of California, Los Angeles Medical Center for Health Sciences
Los Angeles, CA